Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07453602 · ClinicalTrials.gov registry record · Phase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
A Phase 1 study of Eczema and Atopic Dermatitis (AD), sponsored by Arcutis Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT07453602: Recruiting Phase 1 study of Eczema and Atopic Dermatitis (AD), sponsored by Arcutis Biotherapeutics.
NCT07453602 is a Phase 1 study of Eczema and Atopic Dermatitis (AD) that is actively recruiting participants, run by Arcutis Biotherapeutics. The registered enrollment target is 125 participants, below the 202-participant average among 29 other Eczema trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07453602, a Phase 1 study of Eczema and Atopic Dermatitis (AD), is actively recruiting participants, sponsored by Arcutis Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Cohorts, and a Proof-of-Concept (POC) expansion cohort.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL ARQ-234
Study Locations (1)
New Jersey
- Clinical Site 101 - Fair Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What NCT07453602 shows while recruiting
NCT07453602 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 202-participant average among 29 other Eczema trials with a reported enrollment target (38% lower).
The record links to 2 conditions, with Eczema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07453602 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07453602 about?
NCT07453602 is a clinical study titled "Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234". This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants wit...
What is the current status of trial NCT07453602?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2026-03-02. Estimated completion is 2028-04.
What conditions does trial NCT07453602 study?
This clinical trial studies the following conditions: Eczema, Atopic Dermatitis (AD).
What interventions are being tested in trial NCT07453602?
The interventions under investigation include: Placebo (DRUG), ARQ-234 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07453602?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07453602 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07453602's enrollment target sits among peer trials
125 15th of 29 higher than 15 of 29 other Eczema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eczema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
COMPLETED · Phase 1
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI